Merrimack's Prospects Dim As MM-141 Fails Pancreatic Cancer Phase II Trial
Executive Summary
Merrimack Pharmaceuticals has ended development of its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.